3982 Federal Register / Vol. 80, No. 16 / Monday, January 26, 2015 / Notices 

(other than final orders in connection 

with suspension, denial, or revocation 

of registration) has been redelegated to 

the Deputy Assistant Administrator of 

the DEA Office of Diversion Control 

(‘‘Deputy Assistant Administrator’’) 

pursuant to section 7 of 28 CFR pt. 0, 

subpt. R, App. 

In accordance with 21 CFR 

1301.33(a), this is notice that on August 

14, 2014, IRIX Manufacturing, Inc., 309 

Delaware Street, Building 1106, 

Greenville, South Carolina 29605, 

applied to be registered as a bulk 

manufacturer of noroxymorphone 

(9668), a basic class of controlled 

substance listed in schedule II. 

The company plans to manufacture 

the listed controlled substance as API 

for clinical trials. 

Dated: January 9, 2015. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator. 

[FR Doc. 2015–01314 Filed 1–23–15; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Bulk Manufacturer of Controlled 

Substances Application: Siemens 

Healthcare Diagnostics, Inc. 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic classes, and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration in 

accordance with 21 CFR 1301.33(a) on 

or before March 27, 2015. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/ODW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. Request for hearings should be 

sent to: Drug Enforcement 

Administration, Attention: Hearing 

Clerk/LJ, 8701 Morrissette Drive, 

Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: The 

Attorney General has delegated his 

authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of 

manufacturers, distributors, and 

dispensers of controlled substances 

(other than final orders in connection 

with suspension, denial, or revocation 

of registration) has been redelegated to 

the Deputy Assistant Administrator of 

the DEA Office of Diversion Control 

(‘‘Deputy Assistant Administrator’’) 

pursuant to section 7 of 28 CFR pt. 0, 

subpart. R, App. 

In accordance with 21 CFR 

1301.33(a), this is notice that on 

November 19, 2014, Siemens Healthcare 

Diagnostics, Inc., Attn: RA, 100 GBC 

Drive, Mailstop 514, Newark, Delaware 

19702, applied to be registered as a bulk 

manufacturer of the following basic 

classes of controlled substances: 

Controlled substance Schedule 

Tetrahydrocannabinols (7370) ...... I 

Ecgonine (9180) ........................... II 

Morphine (9300) ........................... II 

Thebaine (9333) ........................... II 

The company plans to produce the 

listed controlled substances in bulk to 

be used in the manufacture of reagents 

and drug calibrator controls which are 

DEA exempt products. 

In reference to drug code 7370 the 

company plans to bulk manufacture a 

synthetic tetrahydrocannabinol. No 

other activity for this drug code is 

authorized for this registration. 

Dated: January 9, 2015. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator. 

[FR Doc. 2015–01315 Filed 1–23–15; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Manufacturer of Controlled 

Substances Registration: Pharmacore, 

Inc. 

ACTION: Notice of registration. 

SUMMARY: Pharmacore, Inc. applied to 

be registered as a manufacturer of a 

basic class of controlled substance. The 

DEA grants Pharmacore, Inc. registration 

as a manufacturer of this controlled 

substance. 

SUPPLEMENTARY INFORMATION: By notice 

dated May 28, 2014, and published in 

the Federal Register on June 3, 2014, 79 

FR 31987, Pharmacore, Inc., 4180 

Mendenhall Oaks Parkway, High Point, 

North Carolina 27265, applied to be 

registered as a manufacturer of a certain 

basic class of controlled substance. No 

comments or objections were submitted 

to this notice. 

The Drug Enforcement 

Administration (DEA) has considered 

the factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Pharmacore, Inc. to manufacture this 

basic class of controlled substance is 

consistent with the public interest and 

with United States obligations under 

international treaties, conventions, or 

protocols in effect on May 1, 1971. The 

DEA investigated the company’s 

maintenance of effective controls 

against diversion by inspecting and 

testing the company’s physical security 

systems, verifying the company’s 

compliance with state and local laws, 

and reviewing the company’s 

background and history. 

Therefore, pursuant to 21 U.S.C. 

823(a), and in accordance with 21 CFR 

1301.33, the above-named company is 

granted registration as a bulk 

manufacturer of Noroxymorphone 

(9668), a basic class of controlled 

substance listed in schedule II. 

The company plans to manufacture 

the listed controlled substance as an 

active pharmaceutical ingredient (API) 

for clinical trials. 

Dated: January 9, 2015. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator. 

[FR Doc. 2015–01298 Filed 1–23–15; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Manufacturer of Controlled 

Substances Registration: Lin Zhi 

International, Inc. 

ACTION: Notice of registration. 

SUMMARY: Lin Zhi International, Inc., 

applied to be registered as a 

manufacturer of certain basic classes of 

controlled substances. The DEA grants 

Lin Zhi International, Inc. registration as 

a manufacturer of those controlled 

substances. 

SUPPLEMENTARY INFORMATION: By notice 

dated May 28, 2014, and published in 

the Federal Register on June 4, 2014, 79 

FR 32321, Lin Zhi International, Inc., 

670 Almanor Avenue, Sunnyvale, 

California 94085, applied to be 

registered as a manufacturer of certain 

basic classes of controlled substances. 

No comments or objections were 

submitted to this notice. 

The Drug Enforcement 

Administration (DEA) has considered 

the factors in 21 U.S.C. 823(a) and 

determined that the registration of Lin 

Zhi International, Inc. to manufacture 

the basic classes of controlled 


emcdonald on DSK67QTVN1PROD with NOTICES